Latest Revenue Guidance News

SEEK Limited’s FY2025 half-year results reveal a revenue dip and profit contraction, yet the company delivers a robust free cash flow surge and raises its interim dividend, underscoring resilience amid evolving market conditions.

Infomedia Ltd delivered a robust first half FY25 with a 63% jump in net profit after tax and a 7% rise in underlying cash EBITDA, despite challenges in its SimplePart e-commerce segment. The company’s strategic acquisition of AI specialist Intellegam signals a bold push into data-driven automotive solutions.

Infomedia Ltd reported a steady 2% revenue increase and an 11% rise in NPATA for H1 FY25, alongside a strategic 50% stake acquisition in European AI startup Intellegam, signaling a push for innovation and global expansion.

Findi Limited has expanded its ATM footprint with the State Bank of India by 54%, securing 2,293 additional ATMs and appointing Rothschild & Co for its 2026 Indian IPO. However, FY25 revenue guidance has been revised down due to delays in White Label ATM license commencement.

The a2 Milk Company has reported robust first-half FY25 results, boosting full-year guidance and declaring its inaugural dividend, underscoring confidence in its growth trajectory.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Althea Group Holdings has sharply downgraded its FY25 financial guidance, citing significant challenges in its medicinal cannabis division and the strategic withdrawal from a vape product initiative. Despite the setback, the company highlights ongoing growth in its recreational cannabis operations and a strategic refocus on capital efficiency.

Hansen Technologies has secured a pivotal five-year, A$50 million contract with Virgin Media Limited (VMO2), licensing its cloud-native software suite to enhance VMO2’s operational platforms and customer engagement.

Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.

Fluence Corporation Limited delivered a standout Q4 2024 with $21.2 million revenue and $1 million EBITDA, driven by a strategic shift to higher-margin Smart Product Solutions. The company’s robust $88 million backlog and $50 million in new orders set the stage for ambitious growth in 2025.

Fluence Corporation delivered a standout Q4 2024 with revenue more than doubling prior quarters, overcoming project delays and market headwinds to set the stage for robust growth in 2025.